Table 1 Individual patients and treatment characteristics
Patient number | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 |
|---|---|---|---|---|---|---|---|---|---|
Menstrual status | Premenopausal | Postmenopausal | Premenopausal | Premenopausal | Postmenopausal | Premenopausal | surgically sterilized | Postmenopausal | Premenopausal |
ECOG performance status | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
Hormone receptor status (PR/ER) | PR pos/ER pos | PR pos/ER pos | negative | PR pos/ER pos | PR pos/ER pos | negative | negative | PR pos/ER neg | PR neg/ER pos |
Metastatic at initial diagnosis | No | No | Yes | No | No | No | No | No | Yes |
Number of metastatic sites | |||||||||
Target lesions | 4 | 5 | 1 | 2 | 1 | 3 | 1 | 2 | 1 |
Non-target lesions | 1 | 3 | 1 | 2 | 2 | 2 | 2 | 2 | 1 |
Site of metastatic disease | Liver | Liver | Lung | Lung | Lung | Lymphnodes | Lung | Thoracic wall | Liver |
Bone | Lung | Liver | Lymphnodes | Bone | Skin | Bone | |||
Prior neo-adjuvant treatment | Yes | No | No | No | No | Yes | Yes | Yes | No |
Prior adjuvant treatment | No | Yes | No | Yes | Yes | Yes | No | No | No |
Prior metastatic treatment | |||||||||
Endocrine therapy | first line | No | No | No | No | No | No | No | first line |
Chemotherapy | second line | first/second/third line | first/second/third line | first/second line | first/second line | first/second line | first/second line | first line | first/second/third line |
Trastuzumab | first line | first line | first line | first line | first line | first line | No | first line | first line |
Lapatinib | second line | second line | second line | second line | second line | second line | first line | second line | third line |